Table 2B.
Breast cancer risk in DTC survivors and/or DTC survivors given RAI: cohort and case-control studies from Asia.
| References, country | Study design, setting | Study period, length of FU (y), excluded if FU < x(y), lost to FU (%) | Age range or mean age at DTC diagnosis (y) | DTC cases (TC), DTC with RAI (TR) | BC cases (BT), BC with RAI (BR) | BC risk after TC, BC risk after RAI, Risks (95% CI) | BC risk status after DTC | BC risk status after RAI |
|---|---|---|---|---|---|---|---|---|
| Cho et al. (29), Korea | Cohort study, Korean Central Cancer Registry | 1993–2010, <2 mo excluded | 45.2 y | TC 178,844 | BT 599 | SIR(BT) = 1.20 (1.11–1.30) | ⇑ | |
| Ahn et al. (30), Korea | Cohort study, Registry of Seoul National University Hospital | 1973–2012, 5 y, <2 y excluded | 45.2 y | TC 6,150, TR 3,631 |
BT 99 | HR(BR) = 0.49 (0.22–1.06) | ⇔ | |
| Ahn et al. (30), Korea | Case-control study, Registry of Seoul National University Hospital | 1970–2009, 5 y, <2 | 43.4 y | TC 4,243 | BT 55 | SIR(BT) = 2.45 (1.83–2.96) | ⇑ | |
| Khang et al. (31), Korea | Cohort study, Registry of Seoul National University Hospital | 1976–2010, 7 y, <1 y excluded | 46.4 y | TC 2,468, TR 1,396 |
BT 17 | BT was more frequent, in the no RAI group. | ⇑ | |
| Lu et al. (32), Taiwan | Cohort study, Taiwan Cancer | 1979–2006, 7.1 y, <1 mo excluded | 45.2 y | TC 19,068 | BT 102 | SIR(BT) = 1.42 (1.16–1.72) | ⇑ | |
| Teng et al. (33), Taiwan | Cohort study, Taiwan National Health Insurance Database | 1997–2010, 6.5 y, <1 y | 46 y | TC 20,235, TR 11,799 |
BT 158 | SIR(BT) = 1.48 (1.26–1.73), HR(BR) = 0.99 (0.96–1.02) | ⇑ | ⇔ |
| Lin et al. (34), Taiwan | Cohort study, Taiwan National Health Insurance Database | 2000–2011, 5.9 y | 46 y | TC 10.361, TR 7,069 |
BT 129, BR 91 |
HR(BT) = 1.31(1.07–1.61), HR(BR) = 1.34(1.06–1.69) | ⇑ | ⇑No correlation with activity |
| Sadetzki et al. (35), Israel | Cohort study, Israel National Cancer Registry | 1960–1998, 9.4 y, <1 y excluded | TC 4,911 | BT 70 | SIR(BT) = 1.07 (0.84-1.34) | ⇔ | ||
| Hirsch et al. (36), Israel | Cohort study, Israel National Cancer Registry, Rabin Medical Center Thyroid CancerRegistry | 9.3 y, <2 y excluded | 48.1 y | TC 1,943, TR 1,574 |
BT 49, BR 39 |
The most common SPM was breast cancer(49 from 173) | ⇑ | |
| Izkhakov et al. (37) Israel | Cohort study, Israel National Cancer Registry | 1980–2011, 9.7 y, <1 y excluded | 51.2 y (Jews), 41.4 y (Arabs) | TC 11,538 | BT 258 | SIR(BT) = 1.44(1.26-1.61) | ⇑ |
Some data may be absent in particular rows if the data were not reported in the publication. Numbers in parentheses represent 95% CI's. Up arrows (⇑) denote increased risk, horizontal arrows (⇔) denote no increased risk. Unless otherwise noted, the “DTC patients” group includes both patients receiving RAI and those not receiving RAI.
BC, breast cancer; CI, confidence interval; DTC, differentiated thyroid cancer; FU, follow-up; HR, hazard ratio; RAI, radioiodine therapy; SIR, standardized incidence ratio.